NCT06323889 Longitudinal Monitoring During Intermittent Fasting Protocols in Obese Adults
| NCT ID | NCT06323889 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Zurich |
| Condition | Intermittent Fasting |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-09-23 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2024-09-23 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
LIMITFOOD2 is a randomized clinical intervention study that investigates the effects of two different intermittent fasting protocols compared to a control group on the health of obese adults. A total of 90 participants will be randomized into three equally sized groups: a modified alternate day fasting, a time-restricted eating and a control group, receiving general weight-loss counseling.
Eligibility Criteria
Inclusion Criteria: * Age between 18-50 years, both inclusive * Obese, BMI between 30 and 40 kg/m\^2 (obesity grade I or II), both inclusive * Non-smoker * Good knowledge of German or English language * Stable weight change (change \< +/- 3% current bodyweight) for 3 months prior to the study * HbA1c \< 6.5% without glucose lowering medication * LDL-cholesterol \< 4.6mmol/l without lipid lowering medication Exclusion Criteria: * Participants who have a fasting period of \> 12h per day on a regular basis and do not eat at least three main meals per day. * Current habitual use of dietary supplements (e.g., vitamins, minerals) and/or unwillingness to cease intake of dietary supplements. * Antibiotics intake during 3 months prior to the study due to possible interference with metabolic parameters * Food intolerances, allergies and sensitivities (severe food allergies) or dietary restrictions (e.g. vegan lifestyle) * Acute or chronic infections, malignant disease, renal, hepatic (more than two-fold increased transaminases), pulmonary, neurological (epilepsy) or psychiatric diseases, manifested atherosclerosis, or any other disease precluding participation in the study. * Diabetes * Known alcohol, substance or drug abuse, concomitant medication * More than four hours of physical exercise per week * Women who are pregnant, breast-feeding or aiming to become pregnant during course of the trial * Women and men on hormonal supplementation * Women with an irregular menstrual cycle according to the FIGO criteria * Therapy with antidepressants within the past 6 months * Regular therapy with acetylsalicyclic acid or current medication to regulate blood sugar, blood pressure or lipids * Participants likely to fail to comply with the study protocol * Participants who do not give informed consent
Contact & Investigator
Philipp Gerber, MD
PRINCIPAL INVESTIGATOR
University of Zurich
Frequently Asked Questions
Who can join the NCT06323889 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Intermittent Fasting. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06323889 currently recruiting?
Yes, NCT06323889 is actively recruiting participants. Contact the research team at leonie.moench@usz.ch for enrollment information.
Where is the NCT06323889 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT06323889 clinical trial?
NCT06323889 is sponsored by University of Zurich. The principal investigator is Philipp Gerber, MD at University of Zurich. The trial plans to enroll 90 participants.